Susquehanna International Group, LLP Equillium, Inc. Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$0.66 - $2.33 $19,041 - $67,220	28,850 Added 196.87%	43,504 $30,000
Q1 2024 May 07, 2024	BUY	$0.73 - $3.0 $10,697 - $43,962	14,654 New	14,654 $33,000
Q1 2023 May 16, 2023	SELL	$0.56 - $1.24 $10,373 - $22,969	-18,524 Reduced 55.56%	14,814 $10,000
Q4 2022 Feb 14, 2023	BUY	$0.83 - $2.26 $27,670 - $75,343	33,338 New	33,338 $35,000
Q4 2021 Feb 14, 2022	SELL	$3.77 - $6.99 $53,270 - $98,768	-14,130 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.84 - $6.91 $68,389 - $97,638	14,130 New	14,130 $96,000
Q2 2021 Aug 11, 2021	SELL	$5.11 - $7.64 $112,205 - $167,759	-21,958 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.03 - $10.5 $110,448 - $230,559	21,958 New	21,958 $157,000

11.3M

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $25.8M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.